Key Highlights

  • Third-quarter Revenue fell 17% to $21.6 million from $26.1 million a year earlier.
  • Adjusted EBITDA rose to $6.3 million from $5.1 million, with margins expanding more than 900 basis points.
  • Non-GAAP Net Income was $3.8 million, or $0.20 per diluted share.
  • The company revised its full-year outlook because in-year contracted revenue is tracking below prior-year levels.

OptimizeRx Corp. (NASDAQ:OPRX), a healthcare technology provider that helps life sciences companies reach healthcare professionals and patients, reported third-quarter 2026 results that combined a 17% drop in revenue with higher profit measures. Revenue was $21.6 million against $26.1 million a year earlier, while adjusted EBITDA rose to $6.3 million from $5.1 million. The gap between the Top Line and profit trends is the central feature of the November 11, 2026 update. Pharmaceutical Marketing technology is a competitive area in which revenue often depends on the timing of client campaigns, which can make quarterly results uneven.

Revenue and Profit Measures

GAAP net income was $1.2 million, or $0.06 per share, compared with $0.8 million, or $0.04 per share, a year earlier. Non-GAAP net income was $3.8 million, or $0.20 per diluted share, up from $3.1 million, or $0.16.

Adjusted EBITDA rose about 23% year over year, with margins expanding more than 900 basis points. The company attributed the change to an improved product mix and cost management initiatives.

Platform companies that serve life sciences clients often see revenue vary with campaign budgets and renewal timing. A decline in contracted revenue, as described here, can therefore come from client decisions rather than from changes in the product itself.

Cash and Balance Sheet

Operating cash flow reached $12.9 million for the nine months ended September 30, 2026. Cash and cash equivalents were $22.3 million at quarter end, compared with $23.4 million at the end of 2025.

The cash balance is slightly lower than at the start of the year despite the nine-month operating inflow. The material reviewed does not itemize how cash was used over the period.

Operating cash flow of $12.9 million over the nine months is a useful counterpoint to the lower revenue, because it shows the Business generated cash even as the top line fell. Cash generation and reported profit do not always move together, so both matter.

Contracted Revenue and the Outlook

The company said in-year contracted revenue continues to track below prior-year levels, and it revised its full-year outlook as a result. That is the main reason the revenue trend differs so sharply from the profit trend.

Revenue declines in a platform business can reflect campaign timing, customer budgets or contract structure. The update does not specify which Factor drove the 2026 decline, so the cause cannot be pinned down from the update alone.

A revised outlook tells investors that management expects in-year contracted revenue to be lower than previously assumed. The update does not give the revised range in the sections reviewed, so the size of the reduction cannot be measured here.

What Drove the Margin Change

Margin expansion in a quarter of lower revenue indicates that cost reductions or a shift toward higher-margin products carried more weight than the top-line decline. The company attributes the change to product mix and cost initiatives but does not quantify each factor.

Non-GAAP results exclude items the company treats as outside its core operations. Readers comparing periods should review the company's reconciliation tables to see which adjustments were made.

Margin expansion depends on costs as well as revenue mix. If lower spending is sustainable, adjusted profit can hold at lower revenue, but if revenue declines continue, the cost base would need to shrink further to keep the same margin.

Final Word

OptimizeRx's third quarter shows a smaller top line alongside a larger adjusted profit, a combination that reflects both cost actions and a lower view of contracted revenue. Investors will focus on whether contracted revenue stabilizes and whether margin gains can be sustained at lower revenue levels. The coming quarters will show whether the trend holds. The next quarterly results will show whether contracted revenue steadies and whether margins hold.